Skip to main content

News

You are here

Harpoon Medical to Present an Update on Early Feasibility Study with 1-year Follow-up at the 2016 EACTS Congress

Tuesday, September 27, 2016

BALTIMORE, Sept. 27, 2016 /PRNewswire/ -- Harpoon Medical, Inc., developer of the Harpoon Medical Mitral Valve Repair System for minimally-invasive, beating heart mitral valve repair using artificial ePTFE cords, has been invited to present an update on the patients enrolled in the company's Early Feasibility Study at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) Congress in Barcelona.

Interim results from the first eleven patients enrolled in Harpoon Medical's Early Feasibility Study as of December 31, 2015 were published by Gammie et al. in Circulation (http://dx.doi.org/10.1161/CIRCULATIONAHA.116.022010). Dr. Krzysztof Bartus, Associate Professor of Medicine Jagellonian University John Paul II Hospital, will provide an update on the results of the study at the EACTS Techno College during a session from 15:30-18:00 on Saturday, October 1, 2016. The presentation will include 6-month follow-up data on all thirteen patients enrolled in the study and 1-year follow-up data collected through August 31, 2016.

"I am excited to share Jagellonian University's early experience with the Harpoon device," said Dr. Bartus. "Together with our colleagues from the Institute of Cardiology in Warsaw we have enrolled thirteen patients in the Early Feasibility Study with excellent results and I think the intermediate term data that will be presented at EACTS is quite compelling."

Click here to read the rest of the story @ PRNewswire